News

The FDA has approved the BRAF inhibitor vemurafenib (Zelboraf) as a treatment for patients with BRAFV600-mutated Erdheim-Chester disease (ECD), representing the first approved therapy for this rare blood disorder.

Cyclin D–dependent kinase (CDK) 4/6 inhibitors have proven to be effective treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. But, much like many cancer therapies, there are challenges when it comes to toxicity.

Overall, 159 of the 427 tanning salons were out of compliance, and most of them were in rural locations and southern regions of the United States. Additionally, this was more common in independently owned salons, in states with younger age groups being regulated and in states with more than one tanning regulation.

What can be done to improve quality of life for people with metastatic breast cancer (MBC), which tends to lag in comparison to the experience of those with earlier-stage disease?

Four companies drew the ire of the FDA this week for claiming that their products, derived from marijuana, can treat or even cure cancer.

Laura J. van’t Veer, PhD, discussed determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.

Healthcare providers are quick to bring up side effects like nausea and neuropathy, but are far more apprehensive to talk about sexual issues.

The FDA has granted an accelerated approval to acalabrutinib (Calquence) as a treatment for adult patients with mantle cell lymphoma (MCL) following at least 1 prior therapy, based on objective response rates (ORR) in a single-arm trial.

The average cost of each hospital visit for CINV is over $15,000, according to a recent study.

Genes and gender may play a role in who is more likely to experience chemotherapy-related fatigue, according to a recent study.

The FDA granted Olaparib (Lynparza) a priority review for the treatment of certain patients with breast cancer.

The FDA has approved intravenous (IV) rolapitant (Varubi) for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting (CINV) in adults, according to TESARO, the manufacturer of the agent.

A new study concludes that more education is needed for adults 60 and older who must make treatment decisions about their acute myeloid leukemia (AML) diagnosis.

The PRISM intervention improved psychosocial wellbeing in younger patients with cancer.

The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.

On October 10, 2017, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on education about skin cancer prevention.

The FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma (NHL). This CAR T-cell therapy breaks new ground in treatment for the disease.

Nearly a month after Hurricane Maria left a path of destruction in Puerto Rico, the island is still trying to pick of the pieces.

Radical prostatectomy was not associated with significantly lower all-cause or prostate-cancer mortality than observation.

Researchers from the Centers for Disease Control and Prevention and the National Cancer Institute assessed cancer incidence rates from 2005 to 2014 to identify trends for cancers associated with being overweight or obese.

In April 2017, the American Society of Clinical Oncology released a position statement, Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations, with the goal of educating healthcare providers about challenges faced by LGBTI individuals with cancer.

Improved treatment and early detection mean fewer women in the United States are dying from breast cancer, according to a study released by the American Cancer Society (ACS) that examined trends in the disease.

Survivors of non-Hodgkin lymphoma (NHL) are at a greater risk of heart failure than the general population, according to a recent study published in the Journal of Clinical Oncology.

The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.

FDA approval was given to a new regimen of cabazitaxel (Jevtana) to treat men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The approval is for 20 mg/m2 every 3 weeks in combination with prednisone. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010.

Improved healthcare communication can often lead to better health outcomes for patients.